Skip to main content
main-content

The independent medical news service

Kidney cancer

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

24-01-2019 | Kidney cancer | News | Article

HRQoL greater with nivolumab plus ipilimumab than sunitinib in advanced RCC

Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.

21-01-2019 | Kidney cancer | News | Article

Sustained benefit of VEGFR–TKIs after doublet immunotherapy in metastatic RCC

Second-line treatment with vascular endothelial growth factor receptor–tyrosine kinase inhibitors after failure of nivolumab plus ipilimumab continues to benefit patients with metastatic renal cell carcinoma, report researchers.

18-01-2019 | Kidney cancer | News | Article

Potential ‘risk of harm’ for older women with adjuvant sunitinib for RCC

Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.

11-01-2019 | Oncology | News | Article

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

15-11-2018 | Oncology | News | Article

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

26-10-2018 | Oncology | News | Article

First-line avelumab–axitinib outperforms sunitinib in advanced RCC

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

13-07-2018 | Kidney cancer | News | Article

Germline mutations detected in advanced RCC patients

Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.

19-06-2018 | Oncology | Main feed | News

IMmotion151 PROs add support for first-line atezolizumab plus bevacizumab in mRCC

Patient-reported outcomes from the IMmotion151 study favor atezolizumab plus bevacizumab as a first-line regimen for the treatment of patients with metastatic clear cell renal cell carcinoma.

19-06-2018 | Kidney cancer | News | Article

Need for nephrectomy challenged in some sunitinib-treated metastatic renal cancers

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.

22-05-2018 | Non-small-cell lung cancer | Main feed | News

Atezolizumab receives NICE recommendation for NSCLC

Read more on this UK decision here

26-04-2018 | Kidney cancer | News | Article

FDA backs nivolumab plus ipilimumab for first-line advanced RCC

Click for the details of this announcement

23-03-2018 | Kidney cancer | News | Article

Promising early data reported for avelumab plus axitinib in advanced RCC

Results from the JAVELIN Renal 100 study suggest that avelumab plus axitinib is a tolerable combination, with encouraging antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

20-02-2018 | Kidney cancer | News | Article

Phase Ib trial shows promising treatment combination for advanced RCC

Axitinib plus pembrolizumab can be tolerated and shows promising antitumor activity in patients with advanced renal cell carcinoma, researchers from an early-stage US trial say.

15-02-2018 | Kidney cancer | News | Article

IMmotion151 supports atezolizumab–bevacizumab for untreated metastatic RCC

In patients with previously untreated metastatic renal cell carcinoma, progression-free survival is significantly longer with the combination of atezolizumab and bevacizumab than with sunitinib, phase III study findings indicate.

19-01-2018 | Kidney cancer | News | Article

METEOR supports cabozantinib for patients with advanced RCC and bone metastases

Treatment with the multikinase inhibitor cabozantinib is associated with better outcomes than everolimus therapy in patients with previously treated advanced renal cell carcinoma and bone involvement, suggests a prespecified subgroup analysis of the phase III METEOR trial.

15-01-2018 | Oncology | News | Article

Risks of combining immunotherapy with targeted therapy, radiation highlighted

Adding immune checkpoint inhibitors to targeted therapy or radiotherapy can worsen some of the toxic effects associated with these treatment modalities, indicate two reports published in JAMA Oncology.

21-12-2017 | Oncology | News | Article

FDA approvals announced for advanced RCC, CML

Read more on these decisions here

23-11-2017 | Oncology | News | Article

FDA announces approvals for sunitinib, obinutuzumab

More details on these decisions are a click away

21-09-2017 | Oncology | News | Article

Bevacizumab biosimilar approved in USA

More details about this decision are just a click away

image credits